معرفی
Hao Fang is a Professor of Medicinal Chemistry and Associate Dean at Shandong University's School of Pharmacy, concurrently serving as Vice Director of Scientific Research and International Affairs for Shandong University Cheeloo College of Medicine. His research focuses on developing targeted anticancer therapeutics through structure-based drug design and molecular recognition technologies.
He earned his Ph.D. in Medicinal Chemistry (2001) and B.S. in Pharmacy (1996) from China Pharmaceutical University.
Dr. Fang's research integrates Medicinal Chemistry and Bioorganic Chemistry to combat cancer. His primary work targets histone deacetylase (HDAC), Bcl-2, and Cyclin-dependent kinase (CDK) using structure-based design. In molecular recognition, he develops fluorescent sensors for tumor-cell surface oligosaccharides to enable precise cancer detection. His methodology combines computational modeling, organic synthesis, and biological validation to create novel therapeutic agents.
Analysis of his recent publications reveals a strategic focus on dual-target inhibitors (particularly Bcl-2/Mcl-1 combinations) and HDAC inhibitors. His work increasingly employs computational techniques like pharmacophore modeling and molecular docking to enhance inhibitor specificity. These studies predominantly appear in high-impact medicinal chemistry journals, demonstrating significant contributions to rational anticancer drug development.
His honors include:
- The 8th “My Favorite Advisor” at Shandong University (2016)
- Outstanding Oral Presentation at the 9th International Symposium for Chinese Medicinal Chemists (2014)
- New Century Excellent Talents in University (Ministry of Education, 2012)
- CPA-Servier Young Investigator Award (2011)
- International Medical Communication Young Award (2008)
- Editorial Board memberships for Letters in Drug Design, Acta Pharmaceutica Sinica, and China Pharmaceutical Industry
As principal investigator, Dr. Fang has secured seven major grants including multiple National Natural Science Foundation of China projects (2007-2020) focusing on Mcl-1, Bcl-2, and HDAC inhibitors. His international collaboration with the University of Minnesota highlights his global research impact. His mentorship excellence was recognized through Shandong University's top advising award.
He leads an active research group within Shandong University's Department of Medicinal Chemistry, operating advanced laboratories for synthetic chemistry, computational modeling, and biological testing. His team maintains strong domestic and international collaborations to accelerate anticancer drug discovery.
